Skip to main content
Erschienen in: Journal of Neurology 12/2012

01.12.2012 | Short Commentary

Psoriasis during natalizumab treatment for multiple sclerosis

verfasst von: Jorge Millán-Pascual, Laura Turpín-Fenoll, Pablo Del Saz-Saucedo, Ignacio Rueda-Medina, Santiago Navarro-Muñoz

Erschienen in: Journal of Neurology | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Beta-interferon therapy is known to trigger psoriasis, but this effect has not been previously reported for other multiple sclerosis treatments, such as natalizumab. The following is a case report. A 31-year-old woman affected by psoriasis and relapsing–remitting multiple sclerosis suffered a severe worsening of psoriasis symptoms during natalizumab treatment and acquired a drug-resistant course. This case suggests that aggravation of psoriasis might be a rare side effect of natalizumab, and that clinicians should be aware of the possibility of paradoxical activation of autoimmune diseases during its treatment.
Literatur
1.
Zurück zum Zitat Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3(1):32–38PubMed Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3(1):32–38PubMed
2.
Zurück zum Zitat Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40:233–240PubMedCrossRef Collamer AN, Battafarano DF (2010) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 40:233–240PubMedCrossRef
3.
Zurück zum Zitat Webster GF, Knobler RL, Lublin FD et al (1996) Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patient with multiple sclerosis. J Am AcadDermatol 34:365–367CrossRef Webster GF, Knobler RL, Lublin FD et al (1996) Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patient with multiple sclerosis. J Am AcadDermatol 34:365–367CrossRef
4.
Zurück zum Zitat Lopez-Lerma I, Iranzo P, Herrero C (2009) New-onset psoriasis in a patient treated with interferon beta 1-a. Br J Dermatol 160:716–717PubMedCrossRef Lopez-Lerma I, Iranzo P, Herrero C (2009) New-onset psoriasis in a patient treated with interferon beta 1-a. Br J Dermatol 160:716–717PubMedCrossRef
5.
Zurück zum Zitat Navne JE, Hedegaard U, Bygum A (2005) Activation of psoriasis in patients undergoing treatment with interferon beta. UgeskrLaeger 167:2903–2904 Navne JE, Hedegaard U, Bygum A (2005) Activation of psoriasis in patients undergoing treatment with interferon beta. UgeskrLaeger 167:2903–2904
6.
Zurück zum Zitat La Mantia L, Capsoni F (2010) Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci 31:337–339PubMedCrossRef La Mantia L, Capsoni F (2010) Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci 31:337–339PubMedCrossRef
7.
Zurück zum Zitat Kwok T, Loo J, Guenther L (2010) Psoriasis and multiple sclerosis: is there a link? J Cutan Med Surg 14(4):151–155PubMed Kwok T, Loo J, Guenther L (2010) Psoriasis and multiple sclerosis: is there a link? J Cutan Med Surg 14(4):151–155PubMed
8.
Zurück zum Zitat Ramagolapan SV, Dyment DA, Valdar W et al (2007) Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 6:604–610CrossRef Ramagolapan SV, Dyment DA, Valdar W et al (2007) Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 6:604–610CrossRef
9.
Zurück zum Zitat Ganesvaran G, Greer JM, Pender MP (2009) Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis. Mult Scler 15:763–766PubMedCrossRef Ganesvaran G, Greer JM, Pender MP (2009) Prominent brainstem and cerebellar involvement in multiple sclerosis with psoriasis. Mult Scler 15:763–766PubMedCrossRef
10.
Zurück zum Zitat Ghoreschi K, Brück J, Kellerer C, Deng C et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11):2291–2303PubMedCrossRef Ghoreschi K, Brück J, Kellerer C, Deng C et al (2011) Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 208(11):2291–2303PubMedCrossRef
11.
Zurück zum Zitat Axtell RC, Raman C, Steinman L (2011) Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol 32(6):272–277PubMedCrossRef Axtell RC, Raman C, Steinman L (2011) Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol 32(6):272–277PubMedCrossRef
12.
Zurück zum Zitat Borchers AT, Leibushor N, Cheema GS, Naguwa SM et al (2011) Immune-mediated adverse effects of biological used in the treatment of rheumatic diseases. J Autoimmunity 37:273–288CrossRef Borchers AT, Leibushor N, Cheema GS, Naguwa SM et al (2011) Immune-mediated adverse effects of biological used in the treatment of rheumatic diseases. J Autoimmunity 37:273–288CrossRef
13.
Zurück zum Zitat Tristano G (2010) Neurological adverse events associated with anti-tumor necrosis factor alphatreatment. J Neurol 257(9):1421–1431PubMedCrossRef Tristano G (2010) Neurological adverse events associated with anti-tumor necrosis factor alphatreatment. J Neurol 257(9):1421–1431PubMedCrossRef
14.
Zurück zum Zitat Rivera-Nieves J, Gorfu G, Ley K (2008) Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 14:1715–1735PubMedCrossRef Rivera-Nieves J, Gorfu G, Ley K (2008) Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 14:1715–1735PubMedCrossRef
15.
Zurück zum Zitat Lee SJ, Benveniste EN (1999) Adhesion molecule expression and regulation on cells of the nervous system. J Neuroimmunol 98:77–88PubMedCrossRef Lee SJ, Benveniste EN (1999) Adhesion molecule expression and regulation on cells of the nervous system. J Neuroimmunol 98:77–88PubMedCrossRef
16.
Zurück zum Zitat Bjursten M, Bland PW et al (2005) Long-term treatment with anti-alpha4 integrin antibodies aggravates colitis in G alpha i2-deficient mice. Eur J Immunol 35(8):2274–2283PubMedCrossRef Bjursten M, Bland PW et al (2005) Long-term treatment with anti-alpha4 integrin antibodies aggravates colitis in G alpha i2-deficient mice. Eur J Immunol 35(8):2274–2283PubMedCrossRef
17.
Zurück zum Zitat Monnier-Murina K, Du Thanh A, Merlet-Abrans S et al (2009) Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical immune reaction? Dermatology 219(1):89–90PubMedCrossRef Monnier-Murina K, Du Thanh A, Merlet-Abrans S et al (2009) Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical immune reaction? Dermatology 219(1):89–90PubMedCrossRef
18.
Zurück zum Zitat Durox H, Sparsa A, Lonstand-Ratti V et al (2008) Efalizumab-induced lupus-like syndrome. Acta Derm Venereol 88:270–271PubMed Durox H, Sparsa A, Lonstand-Ratti V et al (2008) Efalizumab-induced lupus-like syndrome. Acta Derm Venereol 88:270–271PubMed
19.
Zurück zum Zitat Lisotti A, Azzaroli F, Brillanti S et al (2012) Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis 44(4):356–357PubMedCrossRef Lisotti A, Azzaroli F, Brillanti S et al (2012) Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis 44(4):356–357PubMedCrossRef
Metadaten
Titel
Psoriasis during natalizumab treatment for multiple sclerosis
verfasst von
Jorge Millán-Pascual
Laura Turpín-Fenoll
Pablo Del Saz-Saucedo
Ignacio Rueda-Medina
Santiago Navarro-Muñoz
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 12/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6713-1

Weitere Artikel der Ausgabe 12/2012

Journal of Neurology 12/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.